Navigation Links
New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO

NEW YORK--(BUSINESS WIRE)--May 29, 2007 - Pfizer said today that results showing potential across numerous types of cancer, such as melanoma, thyroid, liver, non-small cell lung (NSCLC), colorectal (CRC) and renal cell carcinoma (RCC) - a type of advanced kidney cancer - will be presented next week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

"Each person with cancer responds differently to treatment, so it's critical that physicians have the flexibility of trying new options and tailoring regimens to patients' individual needs," said Joe Feczko, MD, chief medical officer at Pfizer. "Pfizer is focused on exploring additional uses for approved products and investigating promising new compounds in a number of different tumor types."

Researchers will present cutting-edge data from the breadth of Pfizer's oncology portfolio, focused in three areas of discovery: anti-angiogenesis, signal transduction and immuno-oncology.


SUTENT(R) (sunitinib malate):

-- Data will be presented from multiple SUTENT abstracts across a wide range of cancers. Highlights include:

-- New data from the phase III trial of SUTENT versus Interferon-alfa (IFN-(alpha)) in previously untreated patients with metastatic RCC.

-- Phase II trial that evaluated the anti-tumor activity of sunitinib malate as a single agent in liver cancer.

-- Phase II study that examined the efficacy and safety of continuous daily dosing of single-agent sunitinib malate in previously treated patients with advanced NSCLC.


-- Phase II data will be presented from five trials evaluating the efficacy of axitinib as a single agent and combined treatment for a number of cancers including advanced pancreatic, thyroid, kidney, NSCLC and metastatic breast cancer. Three key presentations include:

-- Efficacy and safety of axitinib as a single agent in patients with advanced refractory thyroid cancer.

-- Overall survival in patients with advanced pancreatic cancer treated with axitinib in combination with gemcitabine or gemcitabine alone.

-- Single-agent efficacy and safety of axitinib in advanced, refractory NSCLC.

Signal Transduction

-- A phase II trial evaluated the safety and efficacy of the investigational compound CP-751,871 in combination with paclitaxel and carboplatin as first-line treatment for NSCLC and standard therapy (paclitaxel and carboplatin alone).


-- Four different presentations evaluating CP-675,206 in metastatic melanoma and one presentation evaluating CP-675,206 in refractory CRC will be unveiled at ASCO.

-- Results from a multi-dose phase I/II clinical trial that evaluated safety, response, and survival in patients with advanced metastatic melanoma treated with CP-675,206 will be presented in an oral presentation. Two different dosing regimens were evaluated in the phase II arm, providing information on the selected dosing regimen in the phase III program.

Pfizer also announced the expansion of the clinical trial program evaluating the efficacy and safety of sunitinib malate in the treatment of breast cancer. Pfizer has initiated three additional phase III trials to further evaluate sunitinib malate in metastatic breast cancer. This robust research program now includes a total of four phase III and two phase II trials and will include more than 2,600 patients worldwide.

Phase III programs evaluating sunitinib malate in CRC, NSCLC and liver cancer will also be initiated. Professionals interested in learning more about sunitinib malate trials in various cancers can access - a clinical resource for healthcare providers.

"SUTENT has proven to be an important therapy in the treatment of advanced kidney cancer and imatinib-resistant gastrointestinal stromal tumor, for which it is currently appr oved by the FDA," said Charles Baum, MD, vice president of Pfizer Global Research and Development. "We are committed to investigating the role SUTENT may play in the treatment of advanced breast cancer through a comprehensive phase III program."

SUTENT (sunitinib malate) Phase III Trials in Breast Cancer

This phase III research program in advanced breast cancer will investigate sunitinib malate in multiple settings, including first, second and later lines, as both a single agent and in various combinations, including: combined with standard of care (SOC) chemotherapies versus SOC chemotherapies alone and combined with SOC chemotherapies versus other targeted therapies. The studies will evaluate sunitinib malate in patients with various types of advanced breast cancer including HER2 negative and positive, and previously treated advanced triple receptor negative (ER-, PR- and HER2-).

The phase II and III randomized, open-label studies that are currently enrolling include:

Phase III

-- SUN 1094: Sunitinib malate + paclitaxel versus bevacizumab + paclitaxel in first-line advanced breast cancer

-- SUN 1064: Sunitinib malate + docetaxel versus docetaxel alone in HER2- advanced breast cancer

-- SUN 1099: Sunitinib malate + capecitabine versus capecitabine alone in previously treated advanced breast cancer

-- SUN 1107: Single-agent sunitinib malate versus capecitabine in previously treated advanced breast cancer

Phase II

-- SUN 1077: Single-agent sunitinib malate versus chemotherapy in previously treated advanced triple receptor negative (ER-, PR-, and HER2-) breast cancer

-- SUN 1067: Sunitinib malate + trastuzumab versus trastuzumab + placebo in advanced breast cancer

About SUTENT(R) (sunitinib malate)

SUTENT is a multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) after disease progression on or intolera nce to imatinib meylate.

Women of child bearing age who are (or become) pregnant during therapy should be informed of the potential for fetal harm while on Sutent.

Decreases in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) have been observed. Patients with concomitant cardiac conditions should be carefully monitored for clinical signs and symptoms of congestive heart failure.

Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy. CBCs with platelet count and serum chemistries should be performed at the beginning of each treatment cycle for patients receiving treatment with Sutent.

The most common adverse reactions are fatigue, asthenia, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspensia, abdominal pain, constipation, hypertension, rash, hand-foot syndrome, skin discoloration, altered taste, anorexia and bleeding.

For more information on Sutent and Pfizer Oncology please visit

DISCLOSURE NOTICE: The information contained in this release is as of May 29, 2007. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about various products in development, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such products in development as well as their decisions regarding labeling and other matters that could affect their availability or commercial potential; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and in its reports on Form 10-Q and Form 8-K.


Ray Kerins, 212-733-9203


Related medicine technology :

1. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
5. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
8. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
9. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
10. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
11. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
Post Your Comments:
(Date:10/9/2015)... 9, 2015  Eli Lilly and Company (NYSE: ... acquired worldwide rights to Locemia,s intranasal glucagon, a potential ... with insulin. Intranasal glucagon, which is currently in Phase ... rescue treatment for severe hypoglycemia. ... proprietary glucagon nasal powder formulation that is delivered in ...
(Date:10/9/2015)... HILL, N.C. , Oct. 9, 2015 /PRNewswire/ ... or Medical Device environments, corporate communications is perpetually ... communications, corporations and professionals must continuously adjust their ... effectiveness of these adjustments is difficult, but also ... today,s communication options. --> ...
(Date:10/9/2015)... N.C. , Oct. 9, 2015 Regulatory affairs ... --> --> These specialized ... with the plethora of global regulations pertaining to the development ... vital role, regulatory groups largely rely on their own internal ... goals. --> ...
Breaking Medicine Technology:
... sounds are amplified in the inner ear, a finding,that ... mutation or,overdose of drugs, MEMPHIS, Tenn., May 7 ... an electrically powered,amplification mechanism in the cochlea of the ... other mammals. The findings will enable better,understanding of how ...
... Phase 1,clinical trial results for NKTR-118 (oral PEG-naloxol) were ... at the Annual Meeting of the,American Pain Society (APS) ... NKTR-118 was shown to have substantial oral bioavailability,with rapid ... ten times the,known half-life of unPEGylated naloxone., NKTR-118 ...
Cached Medicine Technology:
(Date:10/10/2015)... Concord, NC (PRWEB) , ... October 10, 2015 , ... ... Charlotte Motor Speedway in Concord, NC. Saturday, October 10th, defending race winner, ... Johnson, Joey Logano, Matt Kenseth, Dale Earnhardt Jr., and all of the stars of ...
(Date:10/10/2015)... ... October 10, 2015 , ... Well-known Eastern Pennsylvania ... be recognized by The National Law Journal for inclusion in their second annual ... across the United States who obtained the largest awards for their personal injury ...
(Date:10/9/2015)... Francisco, CA (PRWEB) , ... October 09, 2015 ... ... Geneva, Switzerland for highly sought after internships at the pre-eminent organization in global ... movement dedicated to eliminating social and health disparities. These internships are a mechanism ...
(Date:10/9/2015)... ... 09, 2015 , ... "My spouse and I rely on canes to walk, ... said an inventor from Buffalo, N.Y. "This is not only frustrating but it’s unsanitary. ... REST enables a user to keep a cane upright while it’s not in use. ...
(Date:10/9/2015)... ... October 09, 2015 , ... Head Over Heels Athletic Arts ... developmental camp at the Karolyi Ranch in Huntsville, Texas on October 17-21. , ... Heels girls team head coach and executive director, said. “It's a stepping stone into ...
Breaking Medicine News(10 mins):
... Difficult-to-treat asthma often may have more to do with ... than ineffective medication, according to researchers in Northern Ireland. ... asthma are poorly adherent to inhaled and oral corticosteroid ... City Hospital. The results of the study ...
... Alberta medical researcher being hailed as a world leader in ... pioneering work in the development of a new class of ... The Canadian Cardiovascular Society is giving its 2009 Young ... Y. Oudit (pronounced OO-diht), an assistant professor in the Faculty ...
... 22, 2009 Shire plc (LSE: SHP, NASDAQ: ... data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder ... showed that Vyvanse provided similar concentrations of its ... intranasally or when administered orally. Specifically, the ...
... in U.S. incidence since vaccine was introduced in 2006 , ... infants against rotavirus started in the United States in 2006, ... of rotavirus disease in children, a new government study shows. ... diarrhea in children younger than 5. Before 2006, rotavirus caused ...
... who want shot will be able to get one, eventually ... swine flu infections continue to pour in from across the ... of stocks of the long-awaited H1N1 vaccine are falling behind ... would be on hand by Oct. 15, but not even ...
... Fla. -- While more older adults than ever are ... exists that threatens to turn senior citizens into second-class ... Charness, the William G. Chase Professor of Psychology, and ... that both the attitudes and abilities of older adults ...
Cached Medicine News:
The Radionics XKnife RT2 system provides a precise and versatile stereotactic radiation therapy solution....
Clinac EX Platinum accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
... reliable system. Varian accelerators offers highest ... fastest beam-on times to full stability ... milliseconds, pulse-to-pulse beam control for dynamic ... of multileaf collimator (MLC) products that ...
The Clinac 2300 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
Medicine Products: